With the collaboration of Swiss teams specialized in reproductive genetics, our experts recommend PGT-A and PGT-M testing during IVF in clearly identified situations to provide the best chances of successful pregnancies.

It has been demonstrated that PGT-A and PGT-M tests increase success rates, reduce miscarriages, eliminate the transmission of hereditary diseases to newborns, and shorten the overall time required to achieve a pregnancy.


Our goal is to provide you with clear and transparent information and advice to help you make the right decisions. We invite you to contact us.


In partnership with Swiss teams specialized in the field of reproductive genetics, we can help you deal with genetic issues within your couple using the following methods: preimplantation diagnosis (PGD) and preimplantation genetic screening for aneuploidy (PGTa). 

These innovative methods offer couples who suffer from a hereditary genetic disease, or who have difficulty conceiving, new prospects for fulfilling their desire for a child in complete safety.

Preimplantation diagnosis, also known as PGD, is a cutting-edge procedure that analyzes embryos obtained by in vitro fertilization (IVF) before they are implanted in the uterus. Its main aim is to detect any genetic or chromosomal abnormalities in the embryos, in order to select those that are healthy and able to develop normally. This prevents the transmission of serious genetic diseases to the offspring and improves the chances of IVF success.

PGD is generally recommended in cases where one or both members of the couple are carriers of a known genetic abnormality. Embryos obtained by IVF are developed in the laboratory for a few days, after which one or more cells are harvested for analysis. The diagnostic techniques used may vary, but they all aim to identify the specific genetic anomalies sought. Once the results are available, only healthy embryos free of the anomaly in question are selected for transfer to the woman’s uterus. Preimplantation genetic screening aneuploidy, or PGTa, is a variant of PGD that focuses specifically on the detection of chromosomal abnormalities, such as aneuploidies. Aneuploidies are alterations in the number of chromosomes in an embryo, such as trisomy 21 (Down syndrome) or monosomy X (Turner syndrome). These chromosomal anomalies are often associated with early spontaneous abortions or developmental problems.

PGTa can detect these chromosomal abnormalities in IVF-derived embryos before they are transferred to the uterus. It thus offers couples who have experienced repeated IVF failures or miscarriages a better understanding of the cause of their difficulties, and increased chances of a successful and healthy pregnancy. The PGTa process is similar to that of PGD, with embryonic cell sampling and in-depth analysis for chromosomal abnormalities. Healthy embryos, i‧e. those with a normal chromosome count, are then selected for transfer.

It is important to note that PGD and PGTa are complex procedures and require specialized expertise in reproductive biology and reproductive genetics. Our team and qualified partners are here to guide you, answering all your questions and offering personalized support.

Every situation is unique, and we encourage you to make an appointment with our coordinator to discuss your specific needs. We’ll be there to offer you expert advice, detailed information on procedures and caring support throughout your journey to parenthood.